This comprehensive report provides an in-depth analysis of the global Live and Attenuated Vaccine market, projecting its trajectory through 2032. The study evaluates market dynamics across various segments, including pediatric and adult vaccines, and analyzes applications within hospitals, clinics, and research institutes. By examining key regional trends in the Americas, APAC, Europe, and MEA, the research identifies emerging opportunities and competitive strategies employed by industry leaders such as GlaxoSmithKline, Merck & Co., and Pfizer.

Executive Overview

Global Market Outlook

The global Live and Attenuated Vaccine market is projected to experience significant growth from 2025 through 2032, maintaining a steady compound annual growth rate over the forecast period.

Regional Market Projections

• United States: The market for Live and Attenuated Vaccines in the United States is estimated to increase from 2025 through 2032, growing at a consistent compound annual growth rate.
• China: The market for Live and Attenuated Vaccines in China is estimated to increase from 2025 through 2032, growing at a consistent compound annual growth rate.
• Europe: The market for Live and Attenuated Vaccines in Europe is estimated to increase from 2025 through 2032, growing at a consistent compound annual growth rate.

Report Scope and Methodology

About the Research

LP Information, Inc. (LPI)'s newest research report, the “Live and Attenuated Vaccine Industry Forecast,” reviews total world Live and Attenuated Vaccine sales in 2025. The report provides a comprehensive analysis by region and market sector of projected Live and Attenuated Vaccine sales for the period from 2026 through 2032. With sales broken down by region, market sector, and sub-sector, this report provides a detailed analysis in US$ millions of the world Live and Attenuated Vaccine industry.

Analytical Focus

This Insight Report provides a comprehensive analysis of the global Live and Attenuated Vaccine landscape and highlights key trends related to:

• Product segmentation
• Company formation
• Revenue and market share
• Latest developments
• M&A activity

The report also analyzes the strategies of leading global companies with a focus on:

• Live and Attenuated Vaccine portfolios and capabilities
• Market entry strategies
• Market positions
• Geographic footprints

This analysis aims to better understand these firms’ unique positions in an accelerating global Live and Attenuated Vaccine market. The report evaluates key market trends, drivers, and affecting factors shaping the global outlook and breaks down the forecast by Type, Application, geography, and market size to highlight emerging pockets of opportunity. Utilizing a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study offers a highly nuanced view of the current state and future trajectory in the global Live and Attenuated Vaccine market.

Summary of Findings

This report presents a comprehensive overview, market shares, and growth opportunities of the Live and Attenuated Vaccine market by:

• Product type
• Application
• Key manufacturers
• Key regions and countries

Market Segmentation

By Type

• Pediatric Vaccine
• Adult Vaccines

By Application

• Hospitals
• Clinics
• Diagnostic Centers
• Research Institute
• Others

By Region

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

Competitive Landscape

Key Market Players

The following companies have been profiled based on inputs gathered from primary experts and an analysis of the company's coverage, product portfolio, and market penetration:

• GlaxoSmithKline
• Merck & Co.
• Pfizer, Inc
• Astellas Pharma Inc
• Johnson & Johnson
• CSL Limited
• Emergent BioSolutions, Inc.
• MedImmune, LLC
• Sanofi
• Serum Institute

Market Share

In terms of revenue, the global two largest companies occupied a significant portion of the market share in 2025.

• 1 Scope of the Report

  • 1.1 Market Introduction

  • 1.2 Years Considered

  • 1.3 Research Objectives

  • 1.4 Market Research Methodology

  • 1.5 Research Process and Data Source

  • 1.6 Economic Indicators

  • 1.7 Currency Considered

  • 1.8 Market Estimation Caveats

• 2 Executive Summary

  • 2.1 World Market Overview

    • 2.1.1 Global Live and Attenuated Vaccine Annual Sales 2021-2032

    • 2.1.2 World Current & Future Analysis for Live and Attenuated Vaccine by Geographic Region, 2021, 2025 & 2032

    • 2.1.3 World Current & Future Analysis for Live and Attenuated Vaccine by Country/Region, 2021, 2025 & 2032

  • 2.2 Live and Attenuated Vaccine Segment by Type

    • 2.2.1 Pediatric Vaccine

    • 2.2.2 Adult Vaccines

    • 2.2.3 Live and Attenuated Vaccine Sales by Type

      • 2.2.3.1 Global Live and Attenuated Vaccine Sales Market Share by Type (2021-2026)
      • 2.2.3.2 Global Live and Attenuated Vaccine Revenue and Market Share by Type (2021-2026)
      • 2.2.3.3 Global Live and Attenuated Vaccine Sale Price by Type (2021-2026)

  • 2.3 Live and Attenuated Vaccine Segment by Application

    • 2.3.1 Hospitals

    • 2.3.2 Clinics

    • 2.3.3 Diagnostic Centers

    • 2.3.4 Research Institute

    • 2.3.5 Others

    • 2.3.6 Live and Attenuated Vaccine Sales by Application

      • 2.3.6.1 Global Live and Attenuated Vaccine Sale Market Share by Application (2021-2026)
      • 2.3.6.2 Global Live and Attenuated Vaccine Revenue and Market Share by Application (2021-2026)
      • 2.3.6.3 Global Live and Attenuated Vaccine Sale Price by Application (2021-2026)

• 3 Global by Company

  • 3.1 Global Live and Attenuated Vaccine Breakdown Data by Company

    • 3.1.1 Global Live and Attenuated Vaccine Annual Sales by Company (2021-2026)

    • 3.1.2 Global Live and Attenuated Vaccine Sales Market Share by Company (2021-2026)

  • 3.2 Global Live and Attenuated Vaccine Annual Revenue by Company (2021-2026)

    • 3.2.1 Global Live and Attenuated Vaccine Revenue by Company (2021-2026)

    • 3.2.2 Global Live and Attenuated Vaccine Revenue Market Share by Company (2021-2026)

  • 3.3 Global Live and Attenuated Vaccine Sale Price by Company

  • 3.4 Key Manufacturers Live and Attenuated Vaccine Producing Area Distribution, Sales Area, Product Type

    • 3.4.1 Key Manufacturers Live and Attenuated Vaccine Product Location Distribution

    • 3.4.2 Players Live and Attenuated Vaccine Products Offered

  • 3.5 Market Concentration Rate Analysis

    • 3.5.1 Competition Landscape Analysis

    • 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

  • 3.6 New Products and Potential Entrants

  • 3.7 Market M&A Activity & Strategy

• 4 World Historic Review for Live and Attenuated Vaccine by Geographic Region

  • 4.1 World Historic Live and Attenuated Vaccine Market Size by Geographic Region (2021-2026)

    • 4.1.1 Global Live and Attenuated Vaccine Annual Sales by Geographic Region (2021-2026)

    • 4.1.2 Global Live and Attenuated Vaccine Annual Revenue by Geographic Region (2021-2026)

  • 4.2 World Historic Live and Attenuated Vaccine Market Size by Country/Region (2021-2026)

    • 4.2.1 Global Live and Attenuated Vaccine Annual Sales by Country/Region (2021-2026)

    • 4.2.2 Global Live and Attenuated Vaccine Annual Revenue by Country/Region (2021-2026)

  • 4.3 Americas Live and Attenuated Vaccine Sales Growth

  • 4.4 APAC Live and Attenuated Vaccine Sales Growth

  • 4.5 Europe Live and Attenuated Vaccine Sales Growth

  • 4.6 Middle East & Africa Live and Attenuated Vaccine Sales Growth

• 5 Americas

  • 5.1 Americas Live and Attenuated Vaccine Sales by Country

    • 5.1.1 Americas Live and Attenuated Vaccine Sales by Country (2021-2026)

    • 5.1.2 Americas Live and Attenuated Vaccine Revenue by Country (2021-2026)

  • 5.2 Americas Live and Attenuated Vaccine Sales by Type (2021-2026)

  • 5.3 Americas Live and Attenuated Vaccine Sales by Application (2021-2026)

  • 5.4 United States

  • 5.5 Canada

  • 5.6 Mexico

  • 5.7 Brazil

• 6 APAC

  • 6.1 APAC Live and Attenuated Vaccine Sales by Region

    • 6.1.1 APAC Live and Attenuated Vaccine Sales by Region (2021-2026)

    • 6.1.2 APAC Live and Attenuated Vaccine Revenue by Region (2021-2026)

  • 6.2 APAC Live and Attenuated Vaccine Sales by Type (2021-2026)

  • 6.3 APAC Live and Attenuated Vaccine Sales by Application (2021-2026)

  • 6.4 China

  • 6.5 Japan

  • 6.6 South Korea

  • 6.7 Southeast Asia

  • 6.8 India

  • 6.9 Australia

  • 6.10 China Taiwan

• 7 Europe

  • 7.1 Europe Live and Attenuated Vaccine by Country

    • 7.1.1 Europe Live and Attenuated Vaccine Sales by Country (2021-2026)

    • 7.1.2 Europe Live and Attenuated Vaccine Revenue by Country (2021-2026)

  • 7.2 Europe Live and Attenuated Vaccine Sales by Type (2021-2026)

  • 7.3 Europe Live and Attenuated Vaccine Sales by Application (2021-2026)

  • 7.4 Germany

  • 7.5 France

  • 7.6 UK

  • 7.7 Italy

  • 7.8 Russia

• 8 Middle East & Africa

  • 8.1 Middle East & Africa Live and Attenuated Vaccine by Country

    • 8.1.1 Middle East & Africa Live and Attenuated Vaccine Sales by Country (2021-2026)

    • 8.1.2 Middle East & Africa Live and Attenuated Vaccine Revenue by Country (2021-2026)

  • 8.2 Middle East & Africa Live and Attenuated Vaccine Sales by Type (2021-2026)

  • 8.3 Middle East & Africa Live and Attenuated Vaccine Sales by Application (2021-2026)

  • 8.4 Egypt

  • 8.5 South Africa

  • 8.6 Israel

  • 8.7 Turkey

  • 8.8 GCC Countries

• 9 Market Drivers, Challenges and Trends

  • 9.1 Market Drivers & Growth Opportunities

  • 9.2 Market Challenges & Risks

  • 9.3 Industry Trends

• 10 Manufacturing Cost Structure Analysis

  • 10.1 Raw Material and Suppliers

  • 10.2 Manufacturing Cost Structure Analysis of Live and Attenuated Vaccine

  • 10.3 Manufacturing Process Analysis of Live and Attenuated Vaccine

  • 10.4 Industry Chain Structure of Live and Attenuated Vaccine

• 11 Marketing, Distributors and Customer

  • 11.1 Sales Channel

    • 11.1.1 Direct Channels

    • 11.1.2 Indirect Channels

  • 11.2 Live and Attenuated Vaccine Distributors

  • 11.3 Live and Attenuated Vaccine Customer

• 12 World Forecast Review for Live and Attenuated Vaccine by Geographic Region

  • 12.1 Global Live and Attenuated Vaccine Market Size Forecast by Region

    • 12.1.1 Global Live and Attenuated Vaccine Forecast by Region (2027-2032)

    • 12.1.2 Global Live and Attenuated Vaccine Annual Revenue Forecast by Region (2027-2032)

  • 12.2 Americas Forecast by Country (2027-2032)

  • 12.3 APAC Forecast by Region (2027-2032)

  • 12.4 Europe Forecast by Country (2027-2032)

  • 12.5 Middle East & Africa Forecast by Country (2027-2032)

  • 12.6 Global Live and Attenuated Vaccine Forecast by Type (2027-2032)

  • 12.7 Global Live and Attenuated Vaccine Forecast by Application (2027-2032)

• 13 Key Players Analysis

  • 13.1 GlaxoSmithKline

    • 13.1.1 GlaxoSmithKline Company Information

    • 13.1.2 GlaxoSmithKline Live and Attenuated Vaccine Product Portfolios and Specifications

    • 13.1.3 GlaxoSmithKline Live and Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.1.4 GlaxoSmithKline Main Business Overview

    • 13.1.5 GlaxoSmithKline Latest Developments

  • 13.2 Merck & Co.

    • 13.2.1 Merck & Co. Company Information

    • 13.2.2 Merck & Co. Live and Attenuated Vaccine Product Portfolios and Specifications

    • 13.2.3 Merck & Co. Live and Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.2.4 Merck & Co. Main Business Overview

    • 13.2.5 Merck & Co. Latest Developments

  • 13.3 Pfizer, Inc

    • 13.3.1 Pfizer, Inc Company Information

    • 13.3.2 Pfizer, Inc Live and Attenuated Vaccine Product Portfolios and Specifications

    • 13.3.3 Pfizer, Inc Live and Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.3.4 Pfizer, Inc Main Business Overview

    • 13.3.5 Pfizer, Inc Latest Developments

  • 13.4 Astellas Pharma Inc

    • 13.4.1 Astellas Pharma Inc Company Information

    • 13.4.2 Astellas Pharma Inc Live and Attenuated Vaccine Product Portfolios and Specifications

    • 13.4.3 Astellas Pharma Inc Live and Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.4.4 Astellas Pharma Inc Main Business Overview

    • 13.4.5 Astellas Pharma Inc Latest Developments

  • 13.5 Johnson & Johnson

    • 13.5.1 Johnson & Johnson Company Information

    • 13.5.2 Johnson & Johnson Live and Attenuated Vaccine Product Portfolios and Specifications

    • 13.5.3 Johnson & Johnson Live and Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.5.4 Johnson & Johnson Main Business Overview

    • 13.5.5 Johnson & Johnson Latest Developments

  • 13.6 CSL Limited

    • 13.6.1 CSL Limited Company Information

    • 13.6.2 CSL Limited Live and Attenuated Vaccine Product Portfolios and Specifications

    • 13.6.3 CSL Limited Live and Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.6.4 CSL Limited Main Business Overview

    • 13.6.5 CSL Limited Latest Developments

  • 13.7 Emergent BioSolutions, Inc.

    • 13.7.1 Emergent BioSolutions, Inc. Company Information

    • 13.7.2 Emergent BioSolutions, Inc. Live and Attenuated Vaccine Product Portfolios and Specifications

    • 13.7.3 Emergent BioSolutions, Inc. Live and Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.7.4 Emergent BioSolutions, Inc. Main Business Overview

    • 13.7.5 Emergent BioSolutions, Inc. Latest Developments

  • 13.8 MedImmune, LLC

    • 13.8.1 MedImmune, LLC Company Information

    • 13.8.2 MedImmune, LLC Live and Attenuated Vaccine Product Portfolios and Specifications

    • 13.8.3 MedImmune, LLC Live and Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.8.4 MedImmune, LLC Main Business Overview

    • 13.8.5 MedImmune, LLC Latest Developments

  • 13.9 Sanofi

    • 13.9.1 Sanofi Company Information

    • 13.9.2 Sanofi Live and Attenuated Vaccine Product Portfolios and Specifications

    • 13.9.3 Sanofi Live and Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.9.4 Sanofi Main Business Overview

    • 13.9.5 Sanofi Latest Developments

  • 13.10 Serum Institute

    • 13.10.1 Serum Institute Company Information

    • 13.10.2 Serum Institute Live and Attenuated Vaccine Product Portfolios and Specifications

    • 13.10.3 Serum Institute Live and Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.10.4 Serum Institute Main Business Overview

    • 13.10.5 Serum Institute Latest Developments

• 14 Research Findings and Conclusion